0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
Letters to the Editor   |    
Response to Malik et al. and Brewer Letters
David B. Merrill, M.D.
Am J Psychiatry 2010;167:1127-1127. doi:10.1176/appi.ajp.2010.10040621r
View Author and Article Information
New York, N.Y.

accepted for publication in June 2010.

The author's disclosures accompany the original article.

Accepted June , 2010.

Copyright © American Psychiatric Association

To the Editor: We thank Dr. Malik et al. and Dr. Brewer for their thoughtful comments. Dr. Brewer inquires about the fate of the study in which we reported a post hoc analysis of a large industry-sponsored trial that compared aripiprazole and haloperidol for the treatment of schizophrenia. Our analysis found that the apparent superiority of aripiprazole among patients early in the course of their illness was likely due to substantial side effects in the haloperidol-treated group, perhaps as a result of excessive dosing of haloperidol in the parent trial. We submitted our paper to several journals before it was recently accepted for publication (1). The difficulty of publishing negative results is a well-established phenomenon in clinical trial research in general (2) and for psychiatric trials in particular (3), and it is a primary source of publication bias. Nonpublication of negative results may be a result of authorial or organizational reluctance to submit negative findings, or a relative undervaluing of such studies by reviewers or editors.

We commend Dr. Malik et al. for the creative ways in which they teach residents in their program about the ethical challenges of interacting with the pharmaceutical industry.

Girgis  R;  Merrill  D;  Vorel  S;  Kim  E;  Portland  K;  You  M;  Pikalov  A;  Whitehead  R;  Lieberman  JA:  Aripiprazole vs haloperidol in early-stage schizophrenia.  J Psychiatr Res   (in press)
 
Hopewell  S;  Loudon  K;  Clarke  MJ;  Oxman  AD;  Dickersin  K:  Publication bias in clinical trials due to statistical significance or direction of trials results.  Cochrane Database Syst Rev 2009; 1:MR000006
[PubMed]
 
Turner  EH;  Matthews  AM;  Linardatos  E;  Tell  RA;  Rosenthal  R:  Selective publication of antidepressant trials and its influence on apparent efficacy.  N Engl J Med 2008; 358:252—260
[CrossRef] | [PubMed]
 
References Container
+

References

Girgis  R;  Merrill  D;  Vorel  S;  Kim  E;  Portland  K;  You  M;  Pikalov  A;  Whitehead  R;  Lieberman  JA:  Aripiprazole vs haloperidol in early-stage schizophrenia.  J Psychiatr Res   (in press)
 
Hopewell  S;  Loudon  K;  Clarke  MJ;  Oxman  AD;  Dickersin  K:  Publication bias in clinical trials due to statistical significance or direction of trials results.  Cochrane Database Syst Rev 2009; 1:MR000006
[PubMed]
 
Turner  EH;  Matthews  AM;  Linardatos  E;  Tell  RA;  Rosenthal  R:  Selective publication of antidepressant trials and its influence on apparent efficacy.  N Engl J Med 2008; 358:252—260
[CrossRef] | [PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Books
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 30.  >
APA Practice Guidelines > Chapter 4.  >
APA Practice Guidelines > Chapter 4.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 26.  >
Topic Collections
Psychiatric News
APA Guidelines